CN104334744A - 预测、诊断和治疗特发性肺纤维化的方法 - Google Patents

预测、诊断和治疗特发性肺纤维化的方法 Download PDF

Info

Publication number
CN104334744A
CN104334744A CN201380027564.8A CN201380027564A CN104334744A CN 104334744 A CN104334744 A CN 104334744A CN 201380027564 A CN201380027564 A CN 201380027564A CN 104334744 A CN104334744 A CN 104334744A
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
acid sequence
ipf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380027564.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·R·阿巴斯
J·R·阿罗恩
S·钱德里阿尼
G·贾
N·J·I·卢因-科赫
D·德皮安托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201611178102.8A priority Critical patent/CN107099581B/zh
Publication of CN104334744A publication Critical patent/CN104334744A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201380027564.8A 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法 Pending CN104334744A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611178102.8A CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616394P 2012-03-27 2012-03-27
US61/616,394 2012-03-27
US201261707411P 2012-09-28 2012-09-28
US61/707,411 2012-09-28
PCT/US2013/031178 WO2013148232A1 (en) 2012-03-27 2013-03-14 Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611178102.8A Division CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Publications (1)

Publication Number Publication Date
CN104334744A true CN104334744A (zh) 2015-02-04

Family

ID=49261043

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380027564.8A Pending CN104334744A (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法
CN201611178102.8A Active CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611178102.8A Active CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Country Status (16)

Country Link
US (2) US20160230226A1 (enExample)
EP (2) EP3725892A1 (enExample)
JP (1) JP6404208B2 (enExample)
KR (1) KR102197524B1 (enExample)
CN (2) CN104334744A (enExample)
AR (1) AR090339A1 (enExample)
AU (2) AU2013240344A1 (enExample)
BR (1) BR112014023348A2 (enExample)
CA (1) CA2864884A1 (enExample)
HK (1) HK1206796A1 (enExample)
IL (1) IL256396A (enExample)
MX (2) MX370486B (enExample)
NZ (1) NZ628458A (enExample)
RU (1) RU2014139546A (enExample)
SG (2) SG10201702842SA (enExample)
WO (1) WO2013148232A1 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104792998A (zh) * 2015-03-09 2015-07-22 中国人民解放军第四军医大学 Loxl2抗原用于制备甲状腺癌预示、侵袭、转移试剂盒的应用
CN105400870A (zh) * 2015-11-11 2016-03-16 南方医科大学 CD1c在菌阴肺结核诊断中的应用
WO2016206596A1 (zh) * 2015-06-26 2016-12-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN106319058A (zh) * 2016-08-31 2017-01-11 汪道文 一种检测特发性肺纤维化致病基因的dna文库及其应用
CN108931645A (zh) * 2018-07-26 2018-12-04 北京大学第医院 一种hcv清除后肝纤维化评估系统及评估方法
CN109689892A (zh) * 2016-09-07 2019-04-26 威拉赛特公司 用于检测寻常型间质性肺炎的方法和系统
CN115925920A (zh) * 2022-08-04 2023-04-07 北京顺元天生物制品有限公司 一种基因增强型免疫细胞治疗肝硬化的方法
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
CN119162300A (zh) * 2024-09-12 2024-12-20 中国人民解放军陆军军医大学第一附属医院 用于预测肺纤维化程度及预后情况的标志物、模型及应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035799A1 (ja) 2011-09-06 2013-03-14 株式会社シノテスト ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2015061441A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
JP6312054B2 (ja) * 2013-11-06 2018-04-18 学校法人日本大学 間質性肺炎のバイオマーカー
JP2016537427A (ja) * 2013-11-14 2016-12-01 プロテリス， インコーポレイテッド 一酸化炭素を用いた肺疾患の治療または予防
AU2014386209B2 (en) * 2013-12-20 2021-03-11 President And Fellows Of Harvard College Low shear microfluidic devices and methods of use and manufacturing thereof
WO2015120257A2 (en) * 2014-02-06 2015-08-13 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
US9994905B2 (en) 2014-04-25 2018-06-12 Brown University Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
EP2957634A1 (en) 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
HUE065418T2 (hu) * 2015-10-27 2024-05-28 Univ Taipei Medical Indolin származékok fibrózisos betegségek kezelésére és/vagy megelõzésére
SG11201804243QA (en) * 2015-11-23 2018-06-28 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
JP2019522638A (ja) * 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
WO2018081236A1 (en) * 2016-10-28 2018-05-03 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy
US20200017913A1 (en) * 2017-03-02 2020-01-16 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
IT201700026858A1 (it) * 2017-03-10 2018-09-10 Univ Degli Studi Padova Uso di inibitori delle serin proteasi, in particolare di serpinb3
US20190127456A1 (en) * 2017-10-31 2019-05-02 Fibrogen, Inc. Methods of treating idiopathic pulmonary fibrosis
EP3849580A4 (en) 2018-09-10 2022-06-15 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
WO2020090683A1 (ja) * 2018-10-29 2020-05-07 国立大学法人東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
EP3908668A4 (en) * 2019-01-11 2022-11-09 University of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR PREDICTING LUNG FUNCTION DECLINE RELATED TO IDIOPATHIC PULMONARY FIBROSIS
JP2023536159A (ja) * 2020-07-31 2023-08-23 ジェネンテック， インコーポレイテッド 炎症性呼吸器疾患の増悪を治療するための方法
WO2022182949A2 (en) 2021-02-25 2022-09-01 Lung Therapeutics, Inc. Biomarkers for the treatment of interstitial lung disease
ES2957479B2 (es) * 2022-06-07 2025-07-28 Baigene S L Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis
WO2023245187A2 (en) 2022-06-17 2023-12-21 Apogee Biologics, Inc. Antibodies that bind interleukin 13 and methods of use
EP4619762A1 (en) * 2022-11-14 2025-09-24 Alentis Therapeutics AG Biomarkers for fibrosis treatment using anti-claudin-1 antibodies
CN117747093B (zh) * 2024-02-20 2024-06-07 神州医疗科技股份有限公司 一种特发性肺纤维化诊断模型的构建方法及诊断系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101375157A (zh) * 2006-01-13 2009-02-25 印第安纳大学研究和科技公司 用于治疗涉及对肺中存在的结缔组织自身免疫反应的肺病的分子
CN105169390A (zh) * 2010-12-16 2015-12-23 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
AU658072B2 (en) 1992-06-09 1995-03-30 Hoppe Ag Latch and lockset system
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
EP3718564B1 (en) * 2003-12-23 2023-10-11 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
CA2623429C (en) 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CN101616689A (zh) * 2006-10-05 2009-12-30 森托科尔奥索生物科技公司 用于治疗纤维化的ccr2拮抗剂
WO2008083695A1 (de) 2006-12-20 2008-07-17 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Vorrichtung und verfahren zur messung der intensität des lichtes einer ersten gruppe von lichtquellen einer beleuchtungseinheit
AR066240A1 (es) * 2007-04-23 2009-08-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP5580205B2 (ja) * 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
SG2014014138A (en) * 2008-03-31 2014-07-30 Genentech Inc Compositions and methods for treating and diagnosing asthma
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
EA201100653A1 (ru) * 2008-11-26 2011-12-30 Глаксо Груп Лимитед Лиганды, связывающиеся с интерлейкином-13 (il-13)
US8911960B2 (en) * 2009-06-01 2014-12-16 Case Western Reserve University Method for identifying idiopathic pneumonia progression by measuring the level of mannose-binding protein C

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101375157A (zh) * 2006-01-13 2009-02-25 印第安纳大学研究和科技公司 用于治疗涉及对肺中存在的结缔组织自身免疫反应的肺病的分子
CN105169390A (zh) * 2010-12-16 2015-12-23 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer
US12297503B2 (en) 2009-05-07 2025-05-13 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
CN104792998A (zh) * 2015-03-09 2015-07-22 中国人民解放军第四军医大学 Loxl2抗原用于制备甲状腺癌预示、侵袭、转移试剂盒的应用
WO2016206596A1 (zh) * 2015-06-26 2016-12-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN106290892A (zh) * 2015-06-26 2017-01-04 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN111718413A (zh) * 2015-06-26 2020-09-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN105400870A (zh) * 2015-11-11 2016-03-16 南方医科大学 CD1c在菌阴肺结核诊断中的应用
CN105400870B (zh) * 2015-11-11 2018-09-25 南方医科大学 CD1c在菌阴肺结核诊断中的应用
CN106319058A (zh) * 2016-08-31 2017-01-11 汪道文 一种检测特发性肺纤维化致病基因的dna文库及其应用
CN106319058B (zh) * 2016-08-31 2019-09-10 汪道文 一种检测特发性肺纤维化致病基因的dna文库及其应用
CN109689892A (zh) * 2016-09-07 2019-04-26 威拉赛特公司 用于检测寻常型间质性肺炎的方法和系统
CN108931645A (zh) * 2018-07-26 2018-12-04 北京大学第医院 一种hcv清除后肝纤维化评估系统及评估方法
CN115925920A (zh) * 2022-08-04 2023-04-07 北京顺元天生物制品有限公司 一种基因增强型免疫细胞治疗肝硬化的方法
CN119162300A (zh) * 2024-09-12 2024-12-20 中国人民解放军陆军军医大学第一附属医院 用于预测肺纤维化程度及预后情况的标志物、模型及应用

Also Published As

Publication number Publication date
CA2864884A1 (en) 2013-10-03
EP2831280A4 (en) 2016-02-24
MX2014011503A (es) 2014-12-05
US20160230226A1 (en) 2016-08-11
EP2831280A1 (en) 2015-02-04
SG11201405830VA (en) 2014-10-30
EP3725892A1 (en) 2020-10-21
IL256396A (en) 2018-02-28
MX370486B (es) 2019-12-16
BR112014023348A2 (pt) 2019-03-19
JP2015522246A (ja) 2015-08-06
AR090339A1 (es) 2014-11-05
SG10201702842SA (en) 2017-06-29
KR102197524B1 (ko) 2020-12-31
RU2014139546A (ru) 2016-05-20
EP2831280B1 (en) 2020-04-15
HK1206796A1 (en) 2016-01-15
MX2019015159A (es) 2020-02-19
US20190062836A1 (en) 2019-02-28
AU2013240344A1 (en) 2014-09-18
JP6404208B2 (ja) 2018-10-10
AU2018250393A1 (en) 2018-11-08
CN107099581A (zh) 2017-08-29
WO2013148232A1 (en) 2013-10-03
CN107099581B (zh) 2021-07-13
KR20140143196A (ko) 2014-12-15
NZ628458A (en) 2016-11-25

Similar Documents

Publication Publication Date Title
JP6404208B2 (ja) 特発性肺線維症の予後予測、診断および処置の方法
KR102070761B1 (ko) 천식을 치료 및 진단하기 위한 조성물 및 방법
US10538813B2 (en) Biomarker panel for diagnosis and prediction of graft rejection
Kamiya et al. Immune mechanisms in fibrotic interstitial lung disease
EP3974450A2 (en) Biomarker
CN102639710A (zh) 克罗恩病的基因表达标记
EP2831104A1 (en) Biomarkers for use in integrin therapy applications
WO2014208645A1 (ja) そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法
KR20180036788A (ko) 원형 탈모증 치료를 위한 바이오마커
US20190094223A1 (en) Infiltrating immune cell proportions predict anti-tnf response in colon biopsies
AU2018364987A1 (en) Non-coding RNA for detection of cancer
JP2022106734A (ja) 多発性硬化症の遺伝子発現マーカー及び治療
JP2020531439A (ja) アトピー性皮膚炎の治療及び治療選択のための組成物及び方法
CN116997663A (zh) 类风湿性关节炎发作的标志物和细胞前因
JP6531306B2 (ja) 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
HK1242740B (zh) 预测、诊断和治疗特发性肺纤维化的方法
HK1242740A1 (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
KR101801092B1 (ko) 특발성 페섬유증 진단용 마커 조성물 및 특발성 폐섬유증 진단을 위한 정보제공방법
EP3133400B1 (en) Use of ak6 and gpx5 male fertility related proteins or combination thereof
CN110499365B (zh) Agap9在制备诊断骨关节炎的产品中的应用
Liang et al. Intestinal ILC3s Migrate to the Kidney and Promote Renal Fibrosis via PD-1-mediated Activation
Vuljan Idiopathic Pulmonary Fibrosis (IPF): tissue identification of crucial biomarkers by RNA-Sequencing approach.
Al Mashhadani From Lübeck Institute for Experimental Dermatology (LIED) Supervised by Prof. Hauke Busch
JP2006174740A (ja) アレルギー性疾患の疾患マーカーおよびその利用
HK1152349A (en) Compositions and methods for treating and diagnosing asthma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206796

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150204

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1206796

Country of ref document: HK